Amyloid Beta 1-42 Oligomers

Human Synthetic Amyloid Beta 1-42 Oligomers

Product Specifications

Background

Our Amyloid Beta 1-42 (Aβ42) Oligomers are generated from Amyloid Beta Peptide 1-42 pre-treated with 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) as previously published (1,2) . Our Aβ42 oligomers present as globular oligomers when observed under TEM and AFM, and have a unique dimer/trimer and oligomer signal on a Western Blot with an anti-amyloid beta antibody. Our Aβ42 oligomers were also demonstrated to be toxic to primary rat cortical neurons in a dose-dependent manner. In the brain, amyloid beta peptide (Aβ) is generated by protease cleavage of amyloid precursor protein (APP), which aggregates into oligomers, protofibrils, fibrils and ultimately plaques in neurodegenerative diseases. The accumulation of Aβ plaques in the brain is considered a hallmark of Alzheimer’s disease (AD), and most of the drugs tested for AD in the past 20 years have targeted amyloid beta accumulation (3) . Soluble Aβ oligomers isolated from the brains of AD patients or those generated in vitro potently impaired synapse structure and function (4) . Aβ oligomers generated in vitro were toxic to PC12 cells (5) and SH-SY5Y cells (6) . Aβ was demonstrated to interact with tauopathies to affect neurodegeneration in AD patients (7) and accumulations of Aβ were shown to be associated with lower survival rates in Parkinson’s disease patients with dementia (8) .

Product Name Alternative

Abeta Oligomers, Abeta peptide, Amyloid beta peptide oligomers, Beta amyloid peptide oligomers, amyloid beta precursor protein peptide oligomers, APP

UNSPSC

12352202

UN Code

Non-hazardous

Hazard Statement

Non-hazardous

Gene ID

351

Swiss Prot

P05067

Cellular Locus

Cell Membrane | Intracellular Vesicles

Expression System

Synthetic

Origin Species

Human

Target

Amyloid Beta Oligomers

Conjugation

No Tag

Nature

Synthetic (TFA preparation)

Sequence

DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA

Applications

WB | In vivo Assay | In vitro Assay

Field of Research

Neuroscience | Neurodegeneration | Alzheimer's Disease | Amyloid

Limit Of Detection

Certified >95% pure using mass spec and HPLC. Low endotoxin <2.5 EU/mL @ 1mg/mL.

Concentration

1 mg/ml

Purity

>95%

Weight

0.02

Length

42 amino acids

Buffer

Phosphate buffer (PB) pH 7.4 and 10 mM NaCl

Molecular Weight

4.5 kDa

Precautions

Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.

References & Citations

1. Stine et al. 2003. JBC. 278(13):11612-22. doi: 10.1074/jbc.M210207200 2. Ahmed et al. 2010. Nature Structural & Molecular Biology. 17(5):561-7. doi: 10.1038/nsmb.1799 3. Panza et al. 2019. Nat Rev Neurol. 15:73-88 https://doi.org/10.1038/s41582-018-0116-6 4. Shankar et al. 2008. Nat Med. 14(8):837-842. doi: 10.1038/nm1782 5. Chromy et al. 2003. Biochemistry. 42:12749-12760. doi: 10.1021/bi030029q 6. Kayed et al. 2003. Science. 300(5618): 486-489. doi: 10.1126/science.1079469 7. Want et al. 2016. JAMA Neurol. 73(9):1070-7. doi: 10.1001/jamaneurol.2016.2078 8. Kotzbauer et al. 2012. Arch Neurol. 69(10): 1326-1331. doi: 10.1001/archneurol.2012.1610

Shipping Conditions

Dry Ice. Shipping note: Product will be shipped separately from other products purchased in the same order.

Storage Conditions

-80ºC

Protein Length

42 amino acids

Background Reference 01

1. Stine et al. 2003. JBC. 278 (13) :11612-22. doi: 10.1074/jbc.M210207200 2. Ahmed et al. 2010. Nature Structural & Molecular Biology. 17 (5) :561-7. doi: 10.1038/nsmb.1799 3. Panza et al. 2019. Nat Rev Neurol. 15:73-88 https://doi.org/10.1038/s41582-018-0116-6 4. Shankar et al. 2008. Nat Med. 14 (8) :837-842. doi: 10.1038/nm1782 5. Chromy et al. 2003. Biochemistry. 42:12749-12760. doi: 10.1021/bi030029q 6. Kayed et al. 2003. Science. 300 (5618) : 486-489. doi: 10.1126/science.1079469 7. Want et al. 2016. JAMA Neurol. 73 (9) :1070-7. doi: 10.1001/jamaneurol.2016.2078 8. Kotzbauer et al. 2012. Arch Neurol. 69 (10) : 1326-1331. doi: 10.1001/archneurol.2012.1610